"Within the next five years it is estimated that the development of cell therapy—related products will account for up to $15 billion. The interventions of cell therapy provide efficacious alternative treatment where traditional drugs or medical devices have proved unsatisfactory, yet cell therapy still presents challenges regarding safety and efficacy. This panel will provide an overview on the opportunity and challenges of cell therapy product development."

Objective1:Review the most promising cell therapy products, including stem cell, progenitor cell and lineage-specific cell in regenerative medicine.

Objective2:"Discuss the challenges in the development of a manufacturequality system in cell therapy as compared with the traditional pharmaceutical industry."

Objective3:Offer a view of the integration among clinicians, scientists, industry and regulators to accelerate the delivery of clinical products of cell therapy.